2,3,4-Trimethylbenzene-1-sulfonyl chloride | 96499-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-Trimethylbenzene-1-sulfonyl chloride
• 英文别名: 2,3,4-trimethylbenzenesulfonyl chloride
• CAS: 96499-67-1
• 化学式: C₉H₁₁ClO₂S
• 分子量: 218.7
• InChiKey: AABCIIVNRRHNGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,4-Trimethylbenzene-1-sulfonyl chloride 、 氨 生成 2,3,4-trimethyl-benzenesulfonic acid amide
  参考文献：
  名称：

  MURAMOTO, YOSHIHIRO;ASAKURA, HIDEYUKI;SUZUKI, HITOMI, RES. REPTS FAC. ENG. KINKI UNIV., 1983, N 17, 45-51

  摘要：

  DOI：
• 作为产物：
  描述：

  Sodium;2,3,4-trimethylbenzenesulfonate 、 五氯化磷 生成 2,3,4-Trimethylbenzene-1-sulfonyl chloride
  参考文献：
  名称：

  MURAMOTO, YOSHIHIRO;ASAKURA, HIDEYUKI;SUZUKI, HITOMI, RES. REPTS FAC. ENG. KINKI UNIV., 1983, N 17, 45-51

  摘要：

  DOI：

文献信息

• [EN] TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE TRKA, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2016161572A1

  公开（公告）日：2016-10-13

  The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及式(I)所示的二环杂芳基苯甲酰胺化合物，该化合物是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与髓鞘形成不良或脱髓鞘相关的疾病、障碍、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA的异常活性相关的疾病或障碍。
• [EN] SUBSTITUTED SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONAMIDES SUBSTITUÉS
  申请人：GRUENENTHAL GMBH

  公开号：WO2009090055A1

  公开（公告）日：2009-07-23

  The invention relates to substituted sulfonamide derivatives of the general formula (I'); processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments

  该发明涉及一般式（I'）的取代磺胺基衍生物，其制备方法，含有这些化合物的药物，以及用于制备药物的取代磺胺基衍生物的用途
• [EN] PHENOL COMPOUNDS ALS TOLL -LIKE RECEPTOR 7 AGONISTS<br/>[FR] COMPOSÉS PHÉNOL EN TANT QU'AGONISTES DU RÉCEPTEUR 7 DE TYPE TOLL
  申请人：ASTRAZENECA AB

  公开号：WO2012066335A1

  公开（公告）日：2012-05-24

  The invention concerns compounds of Formula (I): wherein R1, R2, R3 and Q are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful in the preparation of such compounds, pharmaceutical compositions containing them and their use as toll-like receptor 7 agonists.

  这项发明涉及式(I)的化合物：其中R1、R2、R3和Q如描述中所定义。本发明还涉及制备这类化合物的方法，制备这类化合物有用的新中间体，含有它们的药物组合物以及它们作为Toll样受体7激动剂的用途。
• Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof
  申请人：Wang Michael

  公开号：US20140051648A1

  公开（公告）日：2014-02-20

  Disclosed is a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein R1 and R2 are each independently hydrogen, —OH, alkyl, —CF 3 , —OCHF 2 , —OCF 3 or halogen; R3 is cycloalkyl, —OCH 2 CF 3 , —OCH 2 CHF 2 , —OCH 2 CH 2 F or —OCH 2 CH 3 ; R4 is hydrogen, —OH, —O aryl, —OCH 2 aryl, alkyl, cycloalkyl, —CF 3 , —OCHF 2 , —OCF 3 , —OCH 2 CF 3 , —OCH 2 CHF 2 , —OCH 2 CH 2 F or halogen; A is —CX 1 X 2 , wherein X 1 and X 2 are each independently H, F and Cl, and when both X1 and X2 are H, R3 is not —OCH 2 CH 3 . The compound has an activity of inhibitors of sodium-dependent glucose transport protein. Also disclosed is a method for preparing the compound, a pharmaceutical composition comprising the compound, use of the compound and pharmaceutical composition thereof in preparing medicaments of SGLT2 inhibitors and treating related diseases.

  本文揭示了一种具有I式化合物的结构，或者其药学上可接受的盐、溶剂化合物、多晶形态、对映异构体或混合物，其中R1和R2分别独立地为氢、—OH、烷基、—CF3、—OCHF2、—OCF3或卤素；R3为环烷基、—OCH2CF3、—OCH2CHF2、—OCH2CH2F或—OCH2CH3；R4为氢、—OH、—O芳基、—OCH2芳基、烷基、环烷基、—CF3、—OCHF2、—OCF3、—OCH2CF3、—OCH2CHF2、—OCH2CH2F或卤素；A为—CX1X2，其中X1和X2分别独立为H、F和Cl，当X1和X2均为H时，R3不是—OCH2CH3。该化合物具有抑制钠依赖型葡萄糖转运蛋白的活性。还揭示了一种制备该化合物的方法，包括该化合物的药物组合物、使用该化合物和药物组合物制备SGLT2抑制剂和治疗相关疾病的药物的用途。
• Synthesis of Sterically Hindered Secondary Aminoether Alcohols
  申请人：Siskin Michael

  公开号：US20070219400A1

  公开（公告）日：2007-09-20

  Severely sterically hindered secondary aminoether alcohols are prepared by reacting an organic carboxylic acid or alkali metal salt of an organic carboxylic acid with a sulfonyl halide, a sulfuryl halide, a mixed sulfuryl ester halide or a mixed sulfuryl amide halide to yield a sulfonic-carboxylic anhydride compound which is then reacted with a dioxane to cleave the ring of the dioxane, yielding a cleavage product which cleavage product is then aminated with an alkylamine and hydrolyzed with base to yield the severely sterically hindered secondary aminoether alcohol.

  通过将有机羧酸或有机羧酸的碱金属盐与磺酰卤、亚磺酰卤、混合亚磺酰酯卤或混合亚磺酰酰胺卤反应，制备了严重受立体位阻的二级氨醚醇。得到磺酸羧酸酐化合物，然后与二噁烷反应以裂解二噁烷的环，产生一个裂解产物，然后用烷基胺进行胺化，再用碱水解，得到严重受立体位阻的二级氨醚醇。